Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
59
AGNG Quote, Financials, Valuation and Earnings
Last price:
$37.00
Seasonality move
:
1.75%
Day range:
$36.97 - $37.30
52-week range:
$27.43 - $37.30
Dividend yield:
0.85%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
41.8K
Avg. volume:
21.1K
1-year change:
22.92%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
HEAL
Global X HealthTech ETF
|
-- | -- | -- | -- | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
-- | -- | -- | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- |
|
PPH
VanEck Pharmaceutical ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AGNG
Global X Aging Population ETF
|
$37.17 | -- | -- | -- | $0.17 | 0.85% | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
$48.68 | -- | -- | -- | $0.59 | 1.28% | -- |
|
HEAL
Global X HealthTech ETF
|
$31.32 | -- | -- | -- | $0.07 | 0.31% | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
$32.38 | -- | -- | -- | $0.32 | 0.99% | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
$27.94 | -- | -- | -- | $0.16 | 1.1% | -- |
|
PPH
VanEck Pharmaceutical ETF
|
$106.10 | -- | -- | -- | $0.31 | 1.73% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AGNG
Global X Aging Population ETF
|
-- | 0.276 | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 1.683 | -- | -- |
|
HEAL
Global X HealthTech ETF
|
-- | 1.888 | -- | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
-- | 0.904 | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | 0.693 | -- | -- |
|
PPH
VanEck Pharmaceutical ETF
|
-- | 0.005 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
HEAL
Global X HealthTech ETF
|
-- | -- | -- | -- | -- | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
|
PPH
VanEck Pharmaceutical ETF
|
-- | -- | -- | -- | -- | -- |
Global X Aging Population ETF vs. Competitors
-
Which has Higher Returns AGNG or GNOM?
Global X Genomics & Biotechnology ETF has a net margin of -- compared to Global X Aging Population ETF's net margin of --. Global X Aging Population ETF's return on equity of -- beat Global X Genomics & Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AGNGGlobal X Aging Population ETF-- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -
What do Analysts Say About AGNG or GNOM?
Global X Aging Population ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Genomics & Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Aging Population ETF has higher upside potential than Global X Genomics & Biotechnology ETF, analysts believe Global X Aging Population ETF is more attractive than Global X Genomics & Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings AGNGGlobal X Aging Population ETF0 0 0 GNOMGlobal X Genomics & Biotechnology ETF0 0 0 -
Is AGNG or GNOM More Risky?
Global X Aging Population ETF has a beta of 0.740, which suggesting that the stock is 26.042% less volatile than S&P 500. In comparison Global X Genomics & Biotechnology ETF has a beta of 1.257, suggesting its more volatile than the S&P 500 by 25.707%.
-
Which is a Better Dividend Stock AGNG or GNOM?
Global X Aging Population ETF has a quarterly dividend of $0.17 per share corresponding to a yield of 0.85%. Global X Genomics & Biotechnology ETF offers a yield of 1.28% to investors and pays a quarterly dividend of $0.59 per share. Global X Aging Population ETF pays -- of its earnings as a dividend. Global X Genomics & Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGNG or GNOM?
Global X Aging Population ETF quarterly revenues are --, which are smaller than Global X Genomics & Biotechnology ETF quarterly revenues of --. Global X Aging Population ETF's net income of -- is lower than Global X Genomics & Biotechnology ETF's net income of --. Notably, Global X Aging Population ETF's price-to-earnings ratio is -- while Global X Genomics & Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Aging Population ETF is -- versus -- for Global X Genomics & Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGNGGlobal X Aging Population ETF-- -- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- --
-
Which has Higher Returns AGNG or HEAL?
Global X HealthTech ETF has a net margin of -- compared to Global X Aging Population ETF's net margin of --. Global X Aging Population ETF's return on equity of -- beat Global X HealthTech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AGNGGlobal X Aging Population ETF-- -- -- HEALGlobal X HealthTech ETF-- -- -- -
What do Analysts Say About AGNG or HEAL?
Global X Aging Population ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X HealthTech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Aging Population ETF has higher upside potential than Global X HealthTech ETF, analysts believe Global X Aging Population ETF is more attractive than Global X HealthTech ETF.
Company Buy Ratings Hold Ratings Sell Ratings AGNGGlobal X Aging Population ETF0 0 0 HEALGlobal X HealthTech ETF0 0 0 -
Is AGNG or HEAL More Risky?
Global X Aging Population ETF has a beta of 0.740, which suggesting that the stock is 26.042% less volatile than S&P 500. In comparison Global X HealthTech ETF has a beta of 1.216, suggesting its more volatile than the S&P 500 by 21.58%.
-
Which is a Better Dividend Stock AGNG or HEAL?
Global X Aging Population ETF has a quarterly dividend of $0.17 per share corresponding to a yield of 0.85%. Global X HealthTech ETF offers a yield of 0.31% to investors and pays a quarterly dividend of $0.07 per share. Global X Aging Population ETF pays -- of its earnings as a dividend. Global X HealthTech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGNG or HEAL?
Global X Aging Population ETF quarterly revenues are --, which are smaller than Global X HealthTech ETF quarterly revenues of --. Global X Aging Population ETF's net income of -- is lower than Global X HealthTech ETF's net income of --. Notably, Global X Aging Population ETF's price-to-earnings ratio is -- while Global X HealthTech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Aging Population ETF is -- versus -- for Global X HealthTech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGNGGlobal X Aging Population ETF-- -- -- -- HEALGlobal X HealthTech ETF-- -- -- --
-
Which has Higher Returns AGNG or IBRN?
iShares Neuroscience and Healthcare ETF has a net margin of -- compared to Global X Aging Population ETF's net margin of --. Global X Aging Population ETF's return on equity of -- beat iShares Neuroscience and Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AGNGGlobal X Aging Population ETF-- -- -- IBRNiShares Neuroscience and Healthcare ETF-- -- -- -
What do Analysts Say About AGNG or IBRN?
Global X Aging Population ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Neuroscience and Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Aging Population ETF has higher upside potential than iShares Neuroscience and Healthcare ETF, analysts believe Global X Aging Population ETF is more attractive than iShares Neuroscience and Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings AGNGGlobal X Aging Population ETF0 0 0 IBRNiShares Neuroscience and Healthcare ETF0 0 0 -
Is AGNG or IBRN More Risky?
Global X Aging Population ETF has a beta of 0.740, which suggesting that the stock is 26.042% less volatile than S&P 500. In comparison iShares Neuroscience and Healthcare ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AGNG or IBRN?
Global X Aging Population ETF has a quarterly dividend of $0.17 per share corresponding to a yield of 0.85%. iShares Neuroscience and Healthcare ETF offers a yield of 0.99% to investors and pays a quarterly dividend of $0.32 per share. Global X Aging Population ETF pays -- of its earnings as a dividend. iShares Neuroscience and Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGNG or IBRN?
Global X Aging Population ETF quarterly revenues are --, which are smaller than iShares Neuroscience and Healthcare ETF quarterly revenues of --. Global X Aging Population ETF's net income of -- is lower than iShares Neuroscience and Healthcare ETF's net income of --. Notably, Global X Aging Population ETF's price-to-earnings ratio is -- while iShares Neuroscience and Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Aging Population ETF is -- versus -- for iShares Neuroscience and Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGNGGlobal X Aging Population ETF-- -- -- -- IBRNiShares Neuroscience and Healthcare ETF-- -- -- --
-
Which has Higher Returns AGNG or IDNA?
iShares Genomics Immunology and Healthcare ETF has a net margin of -- compared to Global X Aging Population ETF's net margin of --. Global X Aging Population ETF's return on equity of -- beat iShares Genomics Immunology and Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AGNGGlobal X Aging Population ETF-- -- -- IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -
What do Analysts Say About AGNG or IDNA?
Global X Aging Population ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Genomics Immunology and Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Aging Population ETF has higher upside potential than iShares Genomics Immunology and Healthcare ETF, analysts believe Global X Aging Population ETF is more attractive than iShares Genomics Immunology and Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings AGNGGlobal X Aging Population ETF0 0 0 IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 -
Is AGNG or IDNA More Risky?
Global X Aging Population ETF has a beta of 0.740, which suggesting that the stock is 26.042% less volatile than S&P 500. In comparison iShares Genomics Immunology and Healthcare ETF has a beta of 1.067, suggesting its more volatile than the S&P 500 by 6.658%.
-
Which is a Better Dividend Stock AGNG or IDNA?
Global X Aging Population ETF has a quarterly dividend of $0.17 per share corresponding to a yield of 0.85%. iShares Genomics Immunology and Healthcare ETF offers a yield of 1.1% to investors and pays a quarterly dividend of $0.16 per share. Global X Aging Population ETF pays -- of its earnings as a dividend. iShares Genomics Immunology and Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGNG or IDNA?
Global X Aging Population ETF quarterly revenues are --, which are smaller than iShares Genomics Immunology and Healthcare ETF quarterly revenues of --. Global X Aging Population ETF's net income of -- is lower than iShares Genomics Immunology and Healthcare ETF's net income of --. Notably, Global X Aging Population ETF's price-to-earnings ratio is -- while iShares Genomics Immunology and Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Aging Population ETF is -- versus -- for iShares Genomics Immunology and Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGNGGlobal X Aging Population ETF-- -- -- -- IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- --
-
Which has Higher Returns AGNG or PPH?
VanEck Pharmaceutical ETF has a net margin of -- compared to Global X Aging Population ETF's net margin of --. Global X Aging Population ETF's return on equity of -- beat VanEck Pharmaceutical ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AGNGGlobal X Aging Population ETF-- -- -- PPHVanEck Pharmaceutical ETF-- -- -- -
What do Analysts Say About AGNG or PPH?
Global X Aging Population ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand VanEck Pharmaceutical ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Aging Population ETF has higher upside potential than VanEck Pharmaceutical ETF, analysts believe Global X Aging Population ETF is more attractive than VanEck Pharmaceutical ETF.
Company Buy Ratings Hold Ratings Sell Ratings AGNGGlobal X Aging Population ETF0 0 0 PPHVanEck Pharmaceutical ETF0 0 0 -
Is AGNG or PPH More Risky?
Global X Aging Population ETF has a beta of 0.740, which suggesting that the stock is 26.042% less volatile than S&P 500. In comparison VanEck Pharmaceutical ETF has a beta of 0.549, suggesting its less volatile than the S&P 500 by 45.072%.
-
Which is a Better Dividend Stock AGNG or PPH?
Global X Aging Population ETF has a quarterly dividend of $0.17 per share corresponding to a yield of 0.85%. VanEck Pharmaceutical ETF offers a yield of 1.73% to investors and pays a quarterly dividend of $0.31 per share. Global X Aging Population ETF pays -- of its earnings as a dividend. VanEck Pharmaceutical ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGNG or PPH?
Global X Aging Population ETF quarterly revenues are --, which are smaller than VanEck Pharmaceutical ETF quarterly revenues of --. Global X Aging Population ETF's net income of -- is lower than VanEck Pharmaceutical ETF's net income of --. Notably, Global X Aging Population ETF's price-to-earnings ratio is -- while VanEck Pharmaceutical ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Aging Population ETF is -- versus -- for VanEck Pharmaceutical ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGNGGlobal X Aging Population ETF-- -- -- -- PPHVanEck Pharmaceutical ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
70
RGC alert for Jan 8
Regencell Bioscience Holdings Ltd. [RGC] is down 21.5% over the past day.
Buy
64
RVMD alert for Jan 8
Revolution Medicines, Inc. [RVMD] is up 4.61% over the past day.
Sell
38
CRNX alert for Jan 8
Crinetics Pharmaceuticals, Inc. [CRNX] is down 0.23% over the past day.
